Targanta Seeks $86M In IPO For Antibiotic Development

Morrison, Trista
May 2007
BioWorld Today;5/15/2007, Vol. 18 Issue 94, p1
The article reports on the planned initial public offering (IPO) of Cambridge, Massachusetts-based Targanta Therapeutics Corp. As the biotechnology firm prepares to file a new drug application for its antibiotic oritavancin in the first quarter of 2008, it has filed to raise $86.25 million in an IPO. Its preliminary prospectus indicate that proceeds primarily would support oritavancin.


Related Articles

  • Targanta IPO Nets $59.9M To Advance Oritavancin. Harris, Glen // BioWorld Today;10/11/2007, Vol. 18 Issue 198, p3 

    The article reports that Targanta Therapeutics have garnered nearly $60 million in net profit through an initial public offering. The company priced 5.75 million shares of its common stock at $10 each, below the anticipated $12 to $14 per share it initially had hoped for when it filed to go...

  • By the numbers.  // njbiz;10/6/2014, Vol. 27 Issue 40, p1 

    The article presents the number of initial public offerings (IPO) through three quarters of 2014 in New Jersey.

  • Financings Roundup.  // BioWorld Today;10/10/2007, Vol. 18 Issue 197, p6 

    The article reports on the financing agreement established between Osiris Therapeutics Inc. of Columbia, Maryland and its largest shareholder, Friedli Corporate Finance Inc. The $30 million financing may be accessed by Osiris over the next year and will take the form of a common stock issuance...

  • Clovis Follows 2011 IPO With $75M Public Offering. Powers, Marie // BioWorld Today;4/5/2012, Vol. 23 Issue 66, p1 

    The article focuses on the 75 million U.S. dollar underwritten public offering being prepared by biopharmaceutical firm Clovis Oncology. The offering which is set to close on April 10, 2012 will sell 3.75 million shares of common stock priced at 20 U.S. dollars each. It describes the performance...

  • FINANCINGS ROUNDUP.  // BioWorld Today;2/15/2008, Vol. 19 Issue 32, p6 

    This section presents updates on financial transactions in the U.S. biopharmaceutics sector. Underwriters of Acorda Therapeutics Inc. have exercised their entire option to purchase an additional shares of common stock in association with the company's public offering. A common stock purchase...

  • Peplin Raises $17M, Files For $75M IPO On Nasdaq.  // Bioworld Week;8/20/2007, Vol. 15 Issue 34, p2 

    The article reports that the dermatology company Peplin Ltd. in Australia has raised $16.9 million from a private placement. It uses the money to establish a subsidiary in the U.S. to facilitate an initial public offering in the Nasdaq Global Market. On the other hand, subsidiary Peplin Inc. has...

  • Reliant Tries IPO Again; Seeks To Raise $400M.  // Bioworld Week;8/20/2007, Vol. 15 Issue 34, p3 

    The article reports that Liberty Corner, New Jersey-based Reliant Pharmaceuticals Inc. is trying again to complete an initial public offering (IPO) in 2007. It is stated that Reliant has first registered for an IPO, aiming to raise up to $300 million. The company's recent effort is aiming to...

  • Biolex Seeks $70M In IPO For LEX System Products.  // Bioworld Week;8/20/2007, Vol. 15 Issue 34, p3 

    The article reports on the plan of North Carolina-based Biolex Inc. to raise $70 million in an initial public offering (IPO). It is stated that the money to be raised by Biolex will be used to advance its lead product for hepatitis C and other programs. On the other hand, the company uses its...

  • IN THE PIPELINE.  // Investment Dealers' Digest;9/13/2004, Vol. 70 Issue 35, p16 

    This article focuses on the events related to the financial market of the United States that are in the offing. Stonemor Partner is going to bring its Initial Public Offering. Non-IPO list contains the names of Amedisys, Catapult Communications and Wheeling-Pittsburgh.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics